Advertisement

Ovarian Cancer pp 153-167 | Cite as

Ovarian Cancer: Can We Reverse Drug Resistance?

  • David S. P. Tan
  • Joo Ern Ang
  • Stan B. Kaye
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

The treatment of ovarian cancer improved substantially with the introduction of platinum-based chemotherapy in the 1980s. In the 1990s, the results of randomisedcontrolled trials established paclitaxel in combination with a platinum agent as a standard initial chemotherapy for advanced ovarian cancer (1–3). However, over 90% of patients with advanced ovarian cancer will still subsequently die because of clinical failure of chemotherapy, i.e. drug resistance, resulting in an overall 5-year survival of only 30–40%. Clearly, there is a need for more progress in addressing this issue.

Keywords

Ovarian Cancer Clin Oncol Epithelial Ovarian Cancer Ovarian Cancer Cell Nucleotide Excision Repair 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer 2008

Authors and Affiliations

  • David S. P. Tan
    • 1
  • Joo Ern Ang
    • 1
  • Stan B. Kaye
    • 1
  1. 1.Section of Medicine, Institute of Cancer ResearchRoyal Marsden HospitalSuttonUK

Personalised recommendations